Health Trials

Relapsed/Refractory Marginal Zone Lymphoma

1

Review clinical trials related to Relapsed/Refractory Marginal Zone Lymphoma. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma

Efficacy and Safety of Orelabrutinib Combined with Rituximab versus Lenalidomide Combined with Rituximab in Patients with Relapsed/Refractory Marginal Zone Lymphoma

Participants needed: 324
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Beijing InnoCare Pharma Tech Co., Ltd.Updated: Sep 15, 2025Locations: 19
Eligibility criteria

Age ≥ 18 years , either sex. [+4]

Administration of the specified anti-tumor therapies within 2 weeks prior to the... [+4]

Read more